This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous nonesmall-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth factor receptor) genotyping by Sequenom multiplex oncogenotyping assay was feasible in 79% of eligible patients using tumor DNA from either archival specimens and/or plasma. Because patients with EGFR-mutant NSCLC respond well to EGFR tyrosine kinase inhibitor monotherapy alone or in combination with bevacizumab, the combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC. Background: Pharmacodynamic separation of pemetrexed and erlotinib avoids negative cellular interactions and results in antitumor synergy in erlotinib-resistant nonesmall-cell lung cancer (NSCLC) cells, independent of EGFR (epidermal growth factor receptor) genotype. Patients and Methods: Patients with platinum-treated metastatic nonsquamous NSCLC were randomly assigned 1:2 to pemetrexed alone (500 mg/m 2 provided intravenously on day 1) or pemetrexed followed by erlotinib (150 mg provided orally once daily on days 2-17) every 21 days. EGFR genotype was centrally confirmed by Sequenom multiplex oncogenotyping assay. The primary end point was progression-free survival (PFS), which would be considered promising for future study if median PFS was 4.5 months. Results: Of 83 patients enrolled, 79 were randomized to either pemetrexed alone (n ¼ 27) or in combination (n ¼ 52). Fifty-nine (79%) of 75 eligible patients had tumors with confirmed EGFR genotype: 7 with activating mutations and 52 wild type. Median PFS was 4.7 and 2.9 months in the combination and pemetrexed-alone groups, respectively. In patients with EGFR wild-type tumors, median PFS was 5.3 and 3.5 months in the combination and pemetrexed-alone groups, respectively. Objective response rate (29% vs. 10%, P ¼ .17), 6-month PFS (45% vs. 29%, P ¼ .26), and 12-month PFS (23% vs. 10%, P ¼ .28) were all higher in the combination arm. Rash (67% vs. 26%, P ¼ .0007) and diarrhea (44% vs. 11%, P ¼ .003) were significantly more common in the combination arm. Conclusion: In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns. The combination merits further evaluation as maintenance or second-line therapy against new standards in patients with EGFR wild-type advanced NSCLC.
Introduction
Nonesmall-cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States and worldwide. 1, 2 Over the past decade, identification of critical oncogenes driving the pathogenesis of NSCLC has led to the development of an increasing number of novel drugs for molecular cohorts of NSCLC. 3 The presence of gain-of-function somatic mutations in the tyrosine kinase domain of the EGFR (epidermal growth factor receptor) gene defines the first molecular subset of metastatic NSCLC patients whose tumors have an up to 84% response rate to first-line EGFR tyrosine kinase inhibitors (TKIs; ie, erlotinib, gefitinib, or afatinib). These patients have median progression-free survival (PFS) of 9 to 14 months and a median overall survival (OS) of 18 to 36 months. [4] [5] [6] [7] In contrast, little progress has been made in improving outcomes for patients with advanced NSCLC without actionable genetic alterations. 8, 9 The clinical benefit of conventional cytotoxic chemotherapy doublets has reached a plateau in OS of 7 to 8 months in molecularly unselected patients with metastatic NSCLC. 10, 11 In 2004, erlotinib and pemetrexed were approved as monotherapy for unselected patients with advanced NSCLC beyond first-line chemotherapy with an objective response rate of less than 10% and a PFS of 2 to 3 months. 12, 13 Despite the low objective response rate, erlotinib demonstrated a 2-month improvement in OS in EGFR-unknown NSCLC patients, consistent with the cytostatic effect observed in preclinical models. 14, 15 Furthermore, several studies have shown that erlotinib alone has inferior clinical activity compared to chemotherapy in patients with EGFR wild-type NSCLC. [16] [17] [18] [19] [20] Given the different mechanisms of action, modest single-agent activity, and minimal overlapping toxicities of an EGFR TKI and chemotherapy, different combinational strategies have been evaluated. Concurrent administration of an EGFR TKI with standard chemotherapy doublets as first-line therapy did not improve survival compared to chemotherapy doublets alone in unselected NSCLC patients. [21] [22] [23] [24] While EGFR TKIs have cytotoxic effects by inducing apoptosis in EGFR-mutant NSCLC cells, 25, 26 their mechanism of action in EGFR wild-type cells is primarily cytostatic, inducing G1 arrest in vitro, resulting in tumor growth delay in vivo. 14, 15 Thus, together with DNA-damaging chemotherapy, EGFR TKIs could theoretically protect tumor cells from the cytotoxic effect of chemotherapy. We previously reported preclinical studies showing pharmacodynamic separation (PDS) of erlotinib and pemetrexed avoids negative cellular interactions and results in synergistic antitumor effects in erlotinib-resistant NSCLC independent of EGFR genotype, including EGFR-mutant, EGFR wild-type, or KRAS (Kirsten rat sarcoma viral oncogene)-mutant NSCLC cell lines. 15, 27 Phase 1 studies of PDS of erlotinib and pemetrexed support a dose schedule of pemetrexed 500 mg/m 2 on day 1 and erlotinib 150 or 250 mg on days 2 to 16 every 21 days. [28] [29] [30] [31] We thus performed a randomized phase 2 trial of PDS of pemetrexed and intercalated erlotinib versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous NSCLC. Patients were randomized 1:2 using the minimization method to pemetrexed-alone or pemetrexed followed by erlotinib. Pemetrexed 500 mg/m 2 was provided intravenously over 10 minutes on day 1 of each 21-day cycle with standard vitamin B12, folic acid, and dexamethasone, and erlotinib 150 mg orally was provided once daily intermittently from day 2 to 17 for 16 days of each 21-day cycle in the combination arm. Dose interruptions (14 days) or up to 2 reductions were permitted. Patients who stopped pemetrexed because of renal insufficiency or intolerable toxicity could continue erlotinib alone until disease progression. Tumor response was assessed every 2 cycles by computed tomography using RECIST 1.0. 32 Brain magnetic resonance imaging scans were repeated if the brain scan at baseline detected brain metastatic disease. Safety and tolerability were assessed by treatment-emergent adverse events (TEAEs) using National Cancer Institute Common Toxicity Criteria 3.0. Treatment was continued until disease progression, severe or intolerable toxicity, withdrawal of consent, or death. The trial (ClinicalTrials.gov identifier NCT00950365) was reviewed and approved by the local institutional review board at each participating institution. All patients provided written informed consent for study participation.
Patients and Methods

EGFR Genotyping Analyses
Archival tumor specimens and serial blood samples were collected in consenting patients only. 
Statistical Methods
The primary end point was PFS, defined as the time from randomization to disease progression or death, whichever occurred first. Stratification factors were gender, prior smoking, and performance status. A sample size of 50 patients in the combination arm would provide 80% power with a type I error rate of 5% to detect at least a 50% increase in the median PFS-that is, from 2.9 months with pemetrexed alone (historical data) to 4.5 months in the combination treatment. Twenty-five patients were randomized to single-agent pemetrexed to confirm that the efficacy in the current study was comparable to the historical control. 33 To account for a w 10% dropout rate, up to 83 patients were planned. The study was not powered for a direct comparison of the 2 treatment arms, which was considered a secondary objective. A 2:1 randomization was used to enhance patient interest and accrual to the experimental arm. Because the cytotoxic synergism of PDS with the pemetrexed and erlotinib combination was mainly observed in EGFR wild-type, nonsquamous NSCLC, 15 we also performed efficacy analyses restricted to those patients with confirmed EGFR wild-type, nonsquamous NSCLC. Other secondary objectives included toxicities and objective response rate, defined as complete response (CR) plus partial response (PR) rates. 34 PFS end points were censored at the date of the last follow-up for patients whose disease had not progressed or who were still alive, respectively, and were analyzed by the Kaplan-Meier method. 35 Descriptive statistics were used to characterize patients at baseline. Figure 1 summarizes the study schema and patient flow. Eightythree patients were enrolled and treated at 3 US academic centers between June 2006 and April 2012. Two patients withdrew (one in each arm) or became ineligible (one in each arm) before receiving any treatment. Seventy-nine patients were randomized and received at least one dose of treatment. Four patients did not have data evaluable for response (2 in each arm; 3 withdrew after receiving one dose of treatment, and 1 had missing data), leaving data of 75 patients evaluable for treatment response (25 and 50 for pemetrexed alone and pemetrexed with erlotinib, respectively). Treatment 
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groups were balanced for patient demographics and disease characteristics at baseline (Table 1) .
EGFR Genotyping
Because collection of archival tumor specimens was not mandated, specimens were available from only 6 (24%) and 14 (28%) patients in the pemetrexed and pemetrexed with erlotinib arms, respectively. Additionally, 17 (68%) and 32 (64%) patients in the respective arms had at least one blood sample collected during the study course (Table 1) . We confirmed that 59 (79%) of 75 evaluable patients had EGFR wild-type (n ¼ 52) or EGFR-mutant (n ¼ 7) genotype. EGFR mutations included exon 19 deletions (n ¼ 5), exon 20 L858R (n ¼ 1), and G719X (n ¼ 1). Additional hot-spot mutations detected by the Sequenom test in EGFR wildtype tumors include KRAS mutations (n ¼ 5), BRAF mutation (n ¼ 1), ALK gene rearrangements (n ¼ 2; confirmed by FISH), ROS1 gene rearrangement (n ¼ 1; confirmed by next-generation sequencing), and MET mutation (n ¼ 1). Collectively, 15 driver mutations (20%) were detected in 75 eligible patients (Table 1) .
Efficacy by Intent-To-Treat and EGFR Mutation Status
At the data cutoff date of January 29, 2015, median PFS was 4.7 months for the combination arm and 2.8 months in the pemetrexedalone arm, confirming the historical value of 2.9 months (Figure 2A ). Median OS was 9.7 and 8.3 months in pemetrexed and erlotinib combination and pemetrexed-alone arms, respectively, for all eligible patients. In patients with confirmed EGFR wild-type tumors, median PFS was 5.3 and 3.5 months in the combination (n ¼ 31) and pemetrexed-alone (n ¼ 21) arms, respectively ( Figure 2B 
One patient with EGFR-mutant (exon 19 deletion) NSCLC received 77 cycles of treatment in the combination arm; disease remained in CR. Seven patients with EGFR-mutant tumors, all in the combination arm, received a median of 13 cycles of treatment and had 2 CR, 1 PR and 2 stable disease of > 6 months. For these patients, median PFS and OS were 11.5 and 15.6 months, respectively. Table 2 summarizes best response to treatment and time-specific PFS in all evaluable patients or patients with EGFR wild-type NSCLC. For those patients with EGFR wild-type NSCLC, combination therapy induced higher rates of CR (6% vs. 0), PR (23% vs. 10%, P ¼ .26), CR þ PR (29% vs. 10%, P ¼ .17), 6-month PFS (45% vs. 29%, P ¼ .26), and 12-month PFS (23% vs. 10%, P ¼ .28) compared to pemetrexed alone.
Tolerability
A total of 139 and 524 cycles were administrated in the pemetrexed-alone (n ¼ 27) and combination (n ¼ 52) arms, respectively. The respective median number of treatment cycles was 4 (range, 1-25) and 6 (range, 1-77). Sixteen patients (64%) receiving pemetrexed alone and 36 (73%) receiving combination therapy discontinued treatment as a result of disease progression. Other reasons for discontinuation included adverse events in 4 (16%) versus 9 (18%), patient withdrawal in 3 (12%) versus 3 (6%), or other reasons (ie, physician discretion for the need of other chemotherapy, spine surgery) in 2 (8%) versus 1 (2%) in the singleagent and combination arms, respectively (Table 3) . 
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Clinical Lung Cancer January 2017 -63 Table 4 summarizes the TEAEs. There were no treatment-related deaths. Although higher incidences of anorexia, nausea, vomiting, mucositis, diarrhea, rash, and hyperglycemia were observed in the combination arm, all have been reported to be from erlotinib alone. Only rash (67% vs. 26%, P ¼ .0007) and diarrhea (44% vs. 11%, P ¼ .003) were observed significantly more often in the combination arm. Dose reduction of pemetrexed was required for 5 patients (20%) in the pemetrexed-alone arm; it was discontinued as a result of toxicity in 4 patients (16%). In the combination arm, dose reduction of pemetrexed alone was required for 7 patients (14%), erlotinib alone for 7 patients (14%), and both pemetrexed and erlotinib for 5 patients (10%); and treatment was discontinued in 9 patients (19%) ( Table 3) .
Discussion
To our knowledge, this is the first randomized phase 2 study that supports the promising clinical synergy between pemetrexed and erlotinib using an intercalating combination schedule in NSCLC patients with EGFR wild-type tumors centrally genotyped by a sensitive, multiplex mutational assay (Sequenom). At the time of study conception, EGFR genotyping was not yet a routine clinical test to guide treatment decisions for patients with advanced nonsquamous NSCLC, and patients with advanced NSCLC only needed to undergo a small tumor biopsy for histologic assessment. Given the rapid development and widespread clinical application of multiplexed oncogene mutational assays, 36, 37 we centrally determined the EGFR genotype status using banked tumor and blood biospecimens from evaluable patients by the Sequenom OncoCarta Panel V1.0 assay, which is a cost-efficient method for quickly and sensitively determining cancer-relevant mutations using archival FFPE or fine-needle aspiration tumor specimens or plasma ctDNA from study patients. 3, [38] [39] [40] [41] Similar to several recently reported studies, [42] [43] [44] [45] [46] the availability of blood ctDNA as an alternative tumor DNA resource has expanded the success of EGFR genotyping from 20 patients (27%) with only archival tumor specimens to 59 patients (79%) using biospecimens from a combination of archival tumor DNA and blood ctDNA. We had confirmed 52 (69%) EGFR wild-type and 7 (9%) EGFR-mutant genotype cases in 75 evaluable patients. We further performed the prespecified efficacy
Figure 2 Kaplan-Meier Curves for PFS. PFS for Second-line Treatment With Pemetrexed and Erlotinib or Pemetrexed Alone in Patients With Molecularly Unselected NSCLC (A) or Patients With EGFR Wild-type NSCLC (B)
Abbreviations: EGFR ¼ epidermal growth factor receptor; HR ¼ hazard ratio; NSCLC ¼ nonesmall-cell lung cancer; PFS ¼ progression-free survival. 
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analyses restricted to these patients with confirmed EGFR wild-type, nonsquamous NSCLC. We found that median PFS was 4.7 months in patients with unselected, nonsquamous NSCLC, which met the primary end point of at least 4.5 months. There were more EGFR-mutant NSCLC tumors in the combination cohort compared to those in the pemetrexed monotherapy cohort, which might account for the differences in the PFS between the 2 groups. We thus restricted our analysis to those patients with EGFR wild-type NSCLC. We found that the median PFS of the combination treatment was 5.3 months in patients with EGFR wild-type NSCLC. This was a hypothesisgenerating analysis only, as there were only 31 patients in the combination arm. The current study was not powered to compare the 2 treatment arms. In a recently published study, median PFS was 4.5 months for ramucirumab and docetaxel combination as second-line treatment in patients with unselected metastatic NSCLC with high TEAEs. 47 Furthermore, single-agent pemetrexed and erlotinib have historically low response rates of < 10%. 12, 13 Consistent with preclinical synergism, 15 we observed PDS of pemetrexed and intercalated erlotinib increased CR and PR (28% and 10%, respectively) in advanced NSCLC with EGFR wild-type tumors.
To place our results in context, several phase 2 studies have determined the clinical efficacy of PDS or intercalated combinations of an EGFR TKI and chemotherapy in unselected or clinically enriched advanced NSCLC patients as first-line therapy. 48, 49 A recently reported second-line study (n ¼ 240) of pemetrexed (day 1) and erlotinib (days 2-14) resulted in statistically significant improvements in PFS and OS compared to either pemetrexed or erlotinib monotherapy in clinically enriched advanced nonsquamous NSCLC patients whose EGFR genotype status was only known in 44 cases (18%). 50 Another study suggested that East
Asian patients treated with pemetrexed and erlotinib combination experienced a longer median PFS (7.4 months) compared to erlotinib (4.5 months) and pemetrexed (4.0 months). 51 Together, PDS of pemetrexed and erlotinib as second-line therapy has promising antitumor activity based on prolongation of PFS. Because patients with EGFR-mutant NSCLC respond well to EGFR TKI monotherapy alone or in combination with bevacizumab, our combination might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type, advanced NSCLC. Among other combinational strategies for an EGFR TKI with chemotherapeutics, minisequencing combination of platinum doublet and intermittent erlotinib followed by erlotinib maintenance used in the FASTACT studies has also shown improved metastatic PFS (7.6 vs. 6.0 months, hazard ratio ¼ 0.57 [95% CI, 0.47-0.69]; P < .0001). 52, 53 However, our study has several unique features compared to the FASTACT studies. First, the FASTACT studies use a triple-drug combination (gemcitabine 1250 mg/m 2 on [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ) every 4 weeks for 6 cycles as first-line therapy, mainly in patients with EGFRmutant lung cancer. Our study, on the other hand, used a double drug combination as second-line therapy mainly in patients with EGFR wild-type NSCLC. Second, FASTACT used combination chemotherapy of gemcitabine plus platinum with intermittent erlotinib (chemotherapy plus erlotinib) or placebo orally (chemotherapy plus placebo) every 4 weeks for 6 cycles. After 6 cycles of combination chemotherapy, patients were randomized to receive either erlotinib monotherapy or placebo continuously, which mimics the maintenance schedule that has shown a survival benefit in chemotherapy-refractory patients. 54, 55 In contrast, our study is a pure second-line study using a different dose schedule of pemetrexed and erlotinib. As expected, the majority of clinical benefit was seen in patients with EGFR wild-type tumors. Although we did not include erlotinib monotherapy as a comparator arm, several recent second-line chemotherapy studies have consistently shown low tumor response rate in advanced NSCLC patients with EGFR wildtype tumors. 50, 51 Our study supports the importance of choosing rational drug combination schedules that should be considered in combining a newer generation of EGFR TKI [56] [57] [58] or other molecularly targeted agents with chemotherapy. Recently, first-generation immune checkpoint inhibitors have become a second-line standard option in patients with advanced or metastatic NSCLC. 59, 60 Because both tumor response to immune checkpoint inhibitors and tumor genomics are extremely heterogeneous, 61, 62 further development of biomarker research and rational combinational strategies are critical to select the molecular subsets of NSCLC patients suitable for different treatment options alone and in combination in the era of precision oncology. Thus, to validate our results, a future prospective study of PDS of pemetrexed and intercalated erlotinib as maintenance or second-line therapy against new second-line standards might be warranted in patients with EGFR wild-type NSCLC tumors using a multiplex cancer biomarker assay containing EGFR genotyping.
Conclusion
This randomized phase 2 study suggested that in patients with advanced EGFR wild-type nonsquamous NSCLC, PDS of pemetrexed and erlotinib has promising antitumor activity based on prolongation of PFS without any new safety concerns. Plasma ctDNA can be a valid alternative biospecimen resource for tumor genotyping.
Clinical Practice Points
Little progress has been made in improving outcomes for patients with advanced NSCLC without actionable genetic alterations. We and others previously reported preclinical studies showing PDS of erlotinib and pemetrexed avoids negative cellular interactions and results in synergistic antitumor effect in erlotinib-resistant NSCLC independent of EGFR genotype, including EGFR-mutant, EGFR-wild-type, or KRAS-mutant NSCLC cell lines. Phase 1 studies have been performed of the safety of PDS of erlotinib and pemetrexed in patients with advanced NSCLC. Our randomized phase 2 study suggested that PDS of pemetrexed and intercalated erlotinib as second-line therapy in patients with advanced nonsquamous NSCLC has a median PFS of 4.7 and 5.3 months in patients with unselected and EGFR wild-type, nonsquamous NSCLC, respectively, which met the primary end point of at least 4.5 months. Plasma ctDNA is a valid alternative biospecimen resource for EGFR genotyping. Because patients with EGFR-mutant NSCLC respond well to EGFR TKI monotherapy alone or in combination with bevacizumab, PDS of pemetrexed and intercalated erlotinib might merit further evaluation as second-line or maintenance therapy against new standards in patients with EGFR wild-type advanced NSCLC using a multiplex biomarker assay containing EGFR genotyping. Our hypothesis-generating study supports the importance of choosing rational drug combination schedules that should be considered in combining a newer generation of EGFR TKI or other molecularly targeted agents with chemotherapy.
